Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC).
Bladder cancer
De Ritis ratio
NMIBC
PFS
RFS
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
05
2020
accepted:
22
07
2020
pubmed:
19
8
2020
medline:
28
9
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
The De Ritis ratio (aspartate aminotransferase/alanine aminotransferase, DRR) has been linked to oncological outcomes in several cancers. We aimed to assess the association of DRR with recurrence-free survival (RFS) and progression-free survival (PFS) in patients with non-muscle-invasive bladder cancer (NMIBC). We conducted a retrospective analysis of 1117 patients diagnosed with NMIBC originating from an established multicenter database. To define the optimal pretreatment DRR cut-off value, we determined a value of 1.2 as having a maximum Youden index value. The overall population was therefore divided into two De Ritis ratio groups using this cut-off (lower, < 1.2 vs. higher, ≥ 1.2). Univariable and multivariable Cox regression analyses were used to investigate the association of DRR with RFS and PFS. The discrimination of the model was evaluated with the Harrel's concordance index (C-index). Overall, 405 (36%) patients had a DRR ≥ 1.2. On univariable Cox regression analysis, DRR was significantly associated with RFS (HR: 1.23, 95% CI 1.02-1.47, p = 0.03), but not with PFS (HR: 0.96, 95% CI 0.65-1.44, p = 0.9). On multivariable Cox regression analysis, which adjusted for the effect of established clinicopathologic features, DRR ≥ 1.2 remained significantly associated with worse RFS (HR:1.21, 95% CI 1.00-1.46, p = 0.04). The addition of DRR only minimally improved the discrimination of a base model that included established clinicopathologic features (C-index = 0.683 vs. C-index = 0.681). On DCA the inclusion of DRR did not improve the net-benefit of the prognostic model. Despite the statistically significant association of the DRR with RFS in patients with NMIBC, it does not seem to add any prognostic or clinical benefit beyond that of currently available clinical factors.
Identifiants
pubmed: 32808107
doi: 10.1007/s00345-020-03384-9
pii: 10.1007/s00345-020-03384-9
pmc: PMC8217037
doi:
Substances chimiques
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1961-1968Références
Babjuk M, Oosterlinck W, Sylvester R (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). 2019 Edition. Presented at the EAU annual congress, Barcelona, 2019; European Association Urology Guidelines Office. ISBN 978-94-92671-07-3
Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S et al (2013) Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109(6):1460–1466
doi: 10.1038/bjc.2013.372
Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ et al (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67(1):74–82
doi: 10.1016/j.eururo.2014.06.040
Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM et al (2011) Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 107(6):898–904
doi: 10.1111/j.1464-410X.2010.09628.x
D’Andrea D, Hassler MR, Abufaraj M, Soria F, Ertl IE, Ilijazi D, Mari A, Foerster B, Egger G, Shariat SF (2018) Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 18(7):695–703
doi: 10.1080/14737140.2018.1474104
Soria F, D'Andrea D, Pohar K, Shariat SF, Lotan Y (2018) Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? Curr Opin Urol 28(6):577–583
doi: 10.1097/MOU.0000000000000545
D'Andrea D, Moschini M, Gust K, Abufaraj M, Ozsoy M, Mathieu R, Soria F, Briganti A, Roupret M, Karakiewicz PI et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle-invasive bladder cancer. Clin Genitourin Cancer 15(5):e755–e764
doi: 10.1016/j.clgc.2017.03.007
Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61(6):1140–1145
doi: 10.1016/S0090-4295(03)00236-X
Wu J, Chen L, Wang Y, Tan W, Huang Z (2019) Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9400 patients. Onco Targ Therap 12:5201–5213
doi: 10.2147/OTT.S204403
Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M (2015) The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol 194(1):30–35
doi: 10.1016/j.juro.2015.01.083
Nishikawa M, Miyake H, Fujisawa M (2016) De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol 34(9):e419–e417 (e415)
doi: 10.1016/j.urolonc.2016.04.001
Wang H, Fang K, Zhang J, Jiang Y, Wang G, Zhang H, Chen T, Shi X, Li Y, Duan F et al (2017) The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients. Int Urol Nephrol 49(8):1391–1398
doi: 10.1007/s11255-017-1618-7
Gorgel SN, Akin Y, Koc EM, Kose O, Ozcan S, Yilmaz Y (2019) Impact of increased aspartate aminotransferase to alanine aminotransferase (De Ritis) ratio in prognosis of testicular cancer. Invest Clin Urol 60(3):169–175
doi: 10.4111/icu.2019.60.3.169
Shariat SF, Milowsky M, Droller MJ (2009) Bladder cancer in the elderly. Urol Oncol 27(6):653–667
doi: 10.1016/j.urolonc.2009.07.020
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033
doi: 10.1126/science.1160809
Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134(5):703–707
doi: 10.1016/j.cell.2008.08.021
Sookoian S, Pirola CJ (2015) Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol 21(3):711–725
doi: 10.3748/wjg.v21.i3.711
Ha YS, Kim SW, Chun SY, Chung JW, Choi SH, Lee JN, Kim BS, Kim HT, Yoo ES, Kwon TG et al (2019) Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy. BMC Urol 19(1):10
doi: 10.1186/s12894-019-0439-7
Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ, Goebell PJ, Malats N (2010) Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28(4):389–400
doi: 10.1016/j.urolonc.2010.02.011
Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT (2009) Critical review of prostate cancer predictive tools. Future Oncol 5(10):1555–1584
doi: 10.2217/fon.09.121
Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF (2015) Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol 68(2):238–253
doi: 10.1016/j.eururo.2015.01.032
Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A (2011) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 50(Suppl 1):61–75
doi: 10.3109/0284186X.2010.542174
Canat L, Ataly HA, Agalarov S, Alkan I, Altunrende F (2018) The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma. Int Braz J Urol Off J Braz Soc Urol 44(2):288–295
doi: 10.1590/s1677-5538.ibju.2017.0173
Ha H, Chung JW, Ha YS, Choi SH, Lee JN, Kim BS, Kim HT, Kim TH, Yoon GS, Kwon TG et al (2019) Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy. Invest Clin Urol 60(6):447–453
doi: 10.4111/icu.2019.60.6.447
Bruchbacher A, Soria F, Hassler M, Shariat SF, D’Andrea D (2018) Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice? Curr Opin Urol 28(6):584–590
doi: 10.1097/MOU.0000000000000546
Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, Shariat SF (2018) Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol 36(9):389–399
doi: 10.1016/j.urolonc.2018.05.014
Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, Mathieu R, Roupret M, Briganti A et al (2016) Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol 34(11):e417–e424 (483)
doi: 10.1016/j.urolonc.2016.05.013
Kimura S, Soria F, D’Andrea D, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M et al (2018) Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer 16(6):e1123–e1132
doi: 10.1016/j.clgc.2018.07.002
Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52(6):1601–1609
doi: 10.1016/j.eururo.2007.09.036